A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and effectiveness of natalizumab (IMSE 1)

The requested reference [87702c0c442157f91752a2d2aea18f51de4da4aa] no longer exists in our database. It has been replaced by the current reference: [9e495dab46c7013708c88b2723ea1098ed48fb74]

Authors
Category Primary study
ConferenceMultiple Sclerosis
Year 2016
This article has no abstract
Epistemonikos ID: ed5c2662e3e625c0f0ee98db8357bd4754e1f273
First added on: Apr 29, 2026